Leica Autiva Spatial Phenotyper: Workflow, Evidence and Limits
Summary
Leica Autiva combines cyclic staining, multiplex imaging and AI analysis for spatial phenotyping. Review its workflow, manufacturer claims and limits for clinical flow cytometry.
The evidence
Leica Microsystems announced the launch of Autiva Spatial Phenotyper on 28 September 2026. The platform combines automated cyclic staining/de-staining, multiplex imaging, an ATTOAuriga reagent ecosystem and Aivia AI-powered analysis within one spatial-biology workflow.
CFCM explainer — the spatial phenotyping chain
Cyclic staining/de-staining → multiplex imaging → AI segmentation and phenotype classification → spatial cell–cell relationships.
Source/credit: CFCM workflow explainer based on the Leica Microsystems launch release, checked 3 October 2026. Alt text: workflow showing cyclic staining, multiplex imaging, AI phenotyping and spatial context.
Leica states that Autiva can process up to four slides in parallel and complete 24-plex experiments overnight. The company also promotes up to threefold higher throughput; CFCM records that figure as a manufacturer claim rather than independently established performance.
Interpretation and limitations
Autiva is a spatial-imaging platform, not a flow cytometer. The “up to 3× higher throughput” statement is manufacturer-generated. The launch does not establish equivalence with flow cytometry, clinical diagnostic performance or IVD authorization.
What this means for laboratories
High-dimensional phenotyping is no longer owned by one measurement architecture. Flow provides very large event counts but loses tissue architecture; spatial imaging preserves location and cell–cell relationships with different throughput, sampling and validation constraints. CFCM should track that adjacent market without presenting it as a replacement for clinical flow.
Explore the evidence
Continue with clinical spectral flow cytometry and flow cytometry learning resources.
Subscribe to CFCM Weekly for clinical flow cytometry evidence and practical learning.
Source Date
September 28, 2026
Event date
September 28, 2026
Commercial Regulatory Status
Commercially available through Leica Microsystems and authorized partners for spatial-biology research. No clinical IVD authorization is established by the cited launch source.
Primary source
Read the source →An announcement is not proof of availability or authorisation. Interpret status within the stated jurisdiction and evidence boundary.
Editor and independence disclosure →CFCM WEEKLY · EVERY SUNDAY
The science behind the signal, in your inbox.
Get evidence-led clinical flow cytometry news, original conference posters, figures from published papers, practical learning pills, an advanced quiz and the story of one CD marker each week. Free. No spam.
Get CFCM Weekly →Complete the form and confirm the email we send you. Unsubscribe any time. Privacy policy.